Clinical Trials

    Showing 1 - 10 of 10 Alzheimer's Disease

    18F-MK-6240 Tau PET and Brain Inflammation in Alzheimer’s Disease

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Nilene Crisci

    Phone: 713.441.3771

    To clarify the role of inflammation in the pathogenesis of AD, it is important to measure inflammation in brain of people with AD and its relationship with abnormal tau, as the disease progresses. So far, there is no in vivo data in humans verifying ... Read more >

    A Phase IIa randomized, double-blind, placebo-controlled study of the effects of L-serine on Mild Cognitive Impairment (MCI)

    Status: Enrolling

    Investigator: Gustavo Roman

    Study Coordinator: Daniel Arnaud Dominguez

    Phone: 346.356.3635

    This is a Phase IIa, randomized, double-blinded, placebo-controlled trial to determine the tolerability of L-serine for Mild Cognitive Impairment patients and assess preliminary indications of efficacy. Efficacy will be assessed by cognitive testing,... Read more >

    A Study of Biological Markers for the Nervous and Immune Systems and Free Radical Mediated Processes in Amyotrophic Lateral Sclerosis (ALS)

    Status: Enrolling

    Investigator: Stanley Appel

    Study Coordinator: Aramide Balogun

    Phone: 713.441.6955

    The purpose of this protocol is to develop and maintain a biospecimen bank comprised of blood, urine, CSF collected during diagnostic evaluations, tissue from biopsies and autopsies collected from patients with neurological disease and non-neurolog... Read more >

    A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

    Status: Enrolling

    Investigator: Juan Toledo Atucha

    Study Coordinator: Reena Boradia

    Phone: 713.441.1150

    The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease. Additional participants will be enrolled to an addendum safety cohort. The participants will be administered ope... Read more >

    AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

    Status: Enrolling

    Investigator: Juan Toledo Atucha

    Study Coordinator: David De Leon Garza

    Phone: 346.238.1555

    The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whethe... Read more >

    Glutathione and Alzheimer's Disease

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Chimaoge Okafor

    Phone: 713.363.7729

    Alzheimer's disease (AD) is associated with significant, progressive cognitive decline. Key defects in mitochondrial fuel metabolism insulin resistance, inflammation and decreased brain glucose uptake are linked to AD. This trial will investigate the... Read more >

    Glutathione in Mild Cognitive Impairment

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Chimaoge Onyechi

    Phone: 713.363.7729

    Elderly humans have an increased risk of dementia which begins as mild defects in memory called mild cognitive impairment. Glutathione (GSH), a key endogenous antioxidant has been linked to cognition. This exploratory study will investigate mechanism... Read more >

    Houston Alzheimer Disease Study

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Andrea Franco Pando

    Phone: 713.441.1150

    The purpose of this study is to clarify at the individual level what genes and changes in the body predispose people to Alzheimer’s disease or other dementias. We will measure changes in brain imaging, body fluids, and memory or thinking abilities. V... Read more >

    Longitudinal Early-onset Alzheimer's Disease Study Protocol (LEADS)

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Jeffrey Ling

    Phone: 713.363.7753

    The Longitudinal Early-onset Alzheimer's Disease Study (LEADS) is a non-randomized, natural history, non-treatment study designed to look at disease progression in individuals with early onset cognitive impairment. Clinical, cognitive, imaging, bioma... Read more >

    Role of Brain Inflammation in Alzheimer’s Disease

    Status: Enrolling

    Investigator: Joseph Masdeu

    Study Coordinator: Nilene Crisci

    Phone: 713.441.3771

    The discovery of AD risk genes coding for proteins involved in inflammation has revived the interest in neuroinflammation (or brain inflammation) in the pathogenesis of AD. To understand the role of inflammation in the pathogenesis of AD, it is impor... Read more >